Aoxing Pharmaceutical Company, Inc., today announced the inauguration of its new Narcotic and Psychotropic Drug Research Center.
Construction of the center was funded by the Reform and Development Commission of Hebei Province in China along with Aoxing Pharma’s Chinese subsidiary, with a total investment of U.S. $2.15 million. This state-of-the art research center occupies 2200m2, and meets current GLP and GMP standards. The center will provide facilities for narcotic and psychotropic drug research and development, including chemical synthesis, transdermal patch formulation, pilot manufacturing, quality review and analytical labs. The center is outfitted with the latest technology, to offer an optimal research environment to the research scientists at Aoxing Pharma.
“We are delighted by the inauguration of the new R&D center, and are honored to receive this powerful endorsement by the Chinese government,” said Mr. Zhenjiang Yue, the Chairman and CEO of Aoxing Pharma. “The government contributed to the funding of this project in recognition of our company’s strong commitment to the narcotic drug and psychiatric treatment business. Government endorsement of our efforts can also be seen in our recent receipt of authorization from the China FDA (CFDA) to initiate four drug programs, including Lorcaserin Hydrochloride tablets and Lorcaserin Hydrochloride API (active pharmaceutical ingredient), weight-reduction drugs for overweight and obese patients, as well as Caffeine tablets (for swallowing) and Caffeine buccal tablets (for dissolving in the mouth), for the management of mental fatigue and headache. With government approval and our new government-funded research facility, we are well positioned to quickly introduce such products into the Chinese pharmaceutical market.”
